Moderna: No earnings, burning cash, analyst target $44 = -17% from $52.40. mRNA platform thesis has not expanded beyond COVID (RSV vaccine is small). Pipeline milestones are binary and multi-year out. Above 200dma but that is momentum without fundamental backing. Downgrading 5→4: negative analyst consensus, cash burn, no near-term revenue catalyst.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
37.9%/yr
±2.4% · revenue growth to justify current price
FCF-Based Reverse DCF
49.1%/yr
±3.9% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~7h).
Eagle will generate this view by the next trading session (~7h).
MRNA FY25: COVID decline offset by pipeline optionality. intismeran melanoma data strong; flu launch critical 2026-2027. Fair value -45B on probability-weighted pipeline; current B valuation reflects ...